Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time

European Journal of Cancer

Volumn 54, Issue , 2016, Pages 40-48

  Lunenburg, Carin A T C ^a   Henricks, Linda M ^b   Guchelaar, Henk Jan ^a   Swen, Jesse J ^a   Deenen, Maarten J ^c   Schellens, Jan H M ^b,d   Gelderblom, Hans ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c CATHARINA HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

5 Fluorouracil; Capecitabine; Dihydropyrimidine dehydrogenase; DPYD; Fluoropyrimidines; Individualised medicine; Pharmacogenomics

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROPYRIMIDINE; FLUOROURACIL; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

CANCER CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG TOXICITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS (TOPIC); PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RISK REDUCTION; ANIMAL; COST BENEFIT ANALYSIS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECONOMICS; ENZYMOLOGY; GENETIC SCREENING; GENETICS; HEALTH CARE COST; METABOLISM; PHARMACOGENETICS; PHENOTYPE; PROCEDURES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CAPECITABINE; COST-BENEFIT ANALYSIS; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FLUOROURACIL; GENETIC TESTING; GENOTYPE; HEALTH CARE COSTS; HUMANS; PHARMACOGENETICS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84951062296     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.11.008     Document Type: Review

References (71)

1. S.M. Offer, N.J. Wegner, C. Fossum, K. Wang, and R.B. Diasio Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity Cancer Res 73 6 2013 Mar 1958 1968
2. M.J. Deenen, A. Cats, C.M. Mandigers, M. Soesan, W.E. Terpstra, J.H. Beijnen, and et al. Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency Ned Tijdschr Geneeskd 156 48 2012 A4934
3. R.B. Diasio, and M.R. Johnson The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil Pharmacology 61 3 2000 Sep 199 203
4. D. Rosmarin, C. Palles, A. Pagnamenta, K. Kaur, G. Pita, M. Martin, and et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS Gut 64 1 2015 Jan 111 120
5. D.B. Longley, D.P. Harkin, and P.G. Johnston 5-fluorouracil: mechanisms of action and clinical strategies Nat Rev Cancer 3 5 2003 May 330 338
6. A.B.P. van Kuilenburg, J. Haasjes, D.J. Richel, L. Zoetekouw, H. van Lenthe, R.A. de Abreu, and et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene Clin Cancer Res 6 12 2000 Dec 4705 4712
7. A.B.P. van Kuilenburg, and J.G. Maring Evaluation of 5-fluorouracil pharmacokinetic models and therapeutic drug monitoring in cancer patients Pharmacogenomics 14 7 2013 May 799 811
8. D. Rosmarin, C. Palles, D. Church, E. Domingo, A. Jones, E. Johnstone, and et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis J Clin Oncol 32 10 2014 Apr 1031 1039
9. S. Terrazzino, S. Cargnin, M. Del Re, R. Danesi, P.L. Canonico, and A.A. Genazzani DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis Pharmacogenomics 14 11 2013 Aug 1255 1272
10. J. Ciccolini, E. Gross, L. Dahan, B. Lacarelle, and C. Mercier Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal Cancer 9 4 2010 Oct 224 228
11. A.M. Lee, Q. Shi, E. Pavey, S.R. Alberts, D.J. Sargent, F.A. Sinicrope, and et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147) J Natl Cancer Inst 106 12 2014 Dec
12. L. Law, J. Rogers, and C. Eng Delayed presentation of DPD deficiency in colorectal cancer J Adv Pract Oncol 5 3 2014 May 205 210
13. L.B. Saltz, J.V. Cox, C. Blanke, L.S. Rosen, L. Fehrenbacher, M.J. Moore, and et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group N Engl J Med 343 13 2000 Sep 905 914
14. R.B. Diasio, and B.E. Harris Clinical pharmacology of 5-fluorouracil Clin Pharm 16 4 1989 Apr 215 237
15. G.D. Heggie, J.P. Sommadossi, D.S. Cross, W.J. Huster, and R.B. Diasio Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 8 1987 Apr 2203 2206
16. D. Vallbohmer, D.Y. Yang, H. Kuramochi, D. Shimizu, K.D. Danenberg, J. Lindebjerg, and et al. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer Int J Oncol 31 2 2007 Aug 413 418
17. M. Scartozzi, E. Maccaroni, R. Giampieri, M. Pistelli, A. Bittoni, M. Del Prete, and et al. 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics 12 2 2011 Feb 251 265
18. H.L. McLeod, J. Sludden, G.I. Murray, R.A. Keenan, A.I. Davidson, K. Park, and et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours Br J Cancer 77 3 1998 461 465
19. G. Toffoli, L. Giodini, A. Buonadonna, M. Berretta, A. De Paoli, S. Scalone, and et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines Int J Cancer 137 12 2015 Dec 2971 2980
20. S.M. Offer, C.C. Fossum, N.J. Wegner, A.J. Stuflesser, G.L. Butterfield, and R.B. Diasio Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity Cancer Res 74 9 2014 May 2545 2554
21. A. Morel, M. Boisdron-Celle, L. Fey, P. Soulie, M.C. Craipeau, S. Traore, and et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance Mol Cancer Ther 5 11 2006 Nov 2895 2904
22. C. Mercier, and J. Ciccolini Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy Clin Colorectal Cancer 6 4 2006 Nov 288 296
23. H.-H. Hsiao, and S.-F. Lin Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency Current Pharmacogenomics 5 1 2007 Mar 31 38
24. H. Ezzeldin, and R.B. Diasio Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration Clin Colorectal Cancer 4 3 2004 Sep 181 189
25. M. Raida, W. Schwabe, P. Hausler, A.B.P. van Kuilenburg, A.H. van Gennip, D. Behnke, and et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls Clin Cancer Res 7 9 2001 2832 2839
26. J.J. Swen, T.W. Huizinga, H. Gelderblom, E.G.E. de Vries, W.J.J. Assendelft, J. Kirchheiner, and et al. Translating pharmacogenomics: challenges on the road to the clinic PLoS Med 4 8 2007 Aug e209
27. Ciccolini J. Integrating pharmacogenetics testing at the bedside: yes we can! Drug metabol drug interact 2013 Aug, Conference: 2nd ESPT Conference "Pharmacogenomics: From Cell to Clinic" Lisbon Portugal, A12.
28. D.A. Goldstein, W.L. Shaib, and C.R. Flowers Costs and effectiveness of genomic testing in the management of colorectal cancer Oncology (Williston Park) 29 3 2015 Mar 175 183
29. M.C. van Staveren, H.J. Guchelaar, A.B.P. van Kuilenburg, H. Gelderblom, and J.G. Maring Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency Pharmacogenomics J 13 5 2013 Oct 389 395
30. D. Meulendijks, L.M. Henricks, G.S. Sonke, M.J. Deenen, T.K. Froehlich, U. Amstutz, and et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data Lancet Oncol 16 16 2015 Dec 1639 1650
31. M. Joerger, A.D. Huitema, H. Boot, A. Cats, V.D. Doodeman, P.H.M. Smits, and et al. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy Cancer Chemother Pharmacol 75 4 2015 Apr 763 772
32. F.S. Falvella, S. Cheli, A. Martinetti, C. Mazzali, R. Iacovelli, C. Maggi, and et al. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan Br J Clin Pharmacol 80 3 2015 Mar 581 588
33. W. Yu, C. Janssens, M. Gwinn, and M.J. Khoury HuGE risk translator. HuGE navigator (version 2.0) 2010 Available at: http://www.hugenavigator.net/HuGENavigator/checkerComplexStartPage.do [accessed 26.02.15]
34. F.S. Falvella, M. Caporale, S. Cheli, A. Martinetti, R. Berenato, C. Maggi, and et al. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase Int J Mol Sci 16 4 2015 8884 8895
35. M.J. Deenen, A. Cats, M.K. Sechterberger, J.L. Severens, P.H.M. Smits, R. Bakker, and et al. Safety, pharmacokinetics (PK), and cost-effectiveness of upfront genotyping of DPYD in fluoropyrimidine therapy J Clin Oncol 29 suppl; abstr 3606 2011 Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2011
36. J. Sistonen, C. Smith, Y.K. Fu, and C.R. Largiader A new DPYD genotyping assay for improving the safety of 5-fluorouracil therapy Clin Chim Acta 414 2012 Dec 109 111
37. J.J. Swen, M. Nijenhuis, A. de Boer, L. Grandia, A.H. Maitland-van der Zee, H. Mulder, and et al. Pharmacogenetics: from bench to byte-an update of guidelines Clin Pharmacol Ther 89 5 2011 May 662 673
38. L.M. Henricks, C.A.T.C. Lunenburg, D. Meulendijks, H. Gelderblom, A. Cats, J.J. Swen, and et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score Pharmacogenomics 16 11 2015 1277 1286
39. M. Pirmohamed Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles Clin Pharmacol Ther 88 6 2010 Dec 862 866
40. N.K. Gillis, and F. Innocenti Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues Clin Pharmacol Ther 96 6 2014 Dec 655 657
41. R. Di Francia, M. Berretta, O. Catapano, L.M.T. Canzoniero, and L. Formisano Molecular diagnostics for pharmacogenomic testing of fluoropyrimidine based-therapy: costs, methods and applications Clin Chem Lab Med 49 7 2011 1105 1111
42. J.J. Swen, I. Wilting, A.L. de Goede, L. Grandia, H. Mulder, D.J. Touw, and et al. Pharmacogenetics: from bench to byte Clin Pharmacol Ther 83 5 2008 May 781 787
43. J.J. Swen, and H.-J. Guchelaar Just how feasible is pharmacogenetic testing in the primary healthcare setting? Pharmacogenomics 13 5 2012 Apr 507 509
44. H.M. Dunnenberger, K.R. Crews, J.M. Hoffman, K.E. Caudle, U. Broeckel, S.C. Howard, and et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers Annu Rev Pharmacol Toxicol 55 2015 89 106
45. M.J. Ratain, and J.A. Johnson Meaningful use of pharmacogenetics Clin Pharmacol Ther 96 6 2014 Dec 650 652
46. M. Boisdron-Celle, O. Capitain, J.-P. Metges, R. Faroux, C. Borg, M.P. Galais, and et al. Prevention of 5-FU-induced health-threatening toxicity by pretherapeutic DPD deficiency screening: medical and economic assessment of a multiparametric approach J Clin Oncol 31 suppl; abstr 3601 2013 Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2013
47. S. Traore, M. Boisdron-Celle, G. Hunault, T. André, A. Morel, V. Guerin-Meyer, and et al. DPD deficiency: medicoeconomic evaluation of pretreatment screening of 5-FU toxicity J Clin Oncol 30 suppl 4; abstr 410 2012 Conference: Gastrointestinal Cancers Symposium San Francisco:01 Feb 2012
48. M. Boisdron-Celle, P. Biason, E. Gamelin, and A. Morel Dihydropyrimidine dehydrogenase and fluoropyrimidines: a review of current dose adaptation practices and the impact on the future of personalized medicine using 5-fluorouracil Colorectal Cancer 2 6 2013 Dec 549 558
49. U.S. Food and Drug Administration Approved drugs: cetuximab in combination with folfiri/therascreen 2012 www.fda.gov
50. E. van Cutsem, C.H. Kohne, E. Hitre, J. Zaluski, C.R. Chang Chien, A. Makhson, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 14 2009 Apr 1408 1417
51. C. Bokemeyer, I. Bondarenko, A. Makhson, J.T. Hartmann, J. Aparicio, F. de Braud, and et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 5 2009 Feb 663 671
52. D.J. Jonker, C.J. O'Callaghan, C.S. Karapetis, J.R. Zalcberg, D. Tu, H.J. Au, and et al. Cetuximab for the treatment of colorectal cancer N Engl J Med 357 20 2007 Nov 2040 2048
53. G. Ahmed, J. O'Keeffe, D.O. Mullane, A. Bransfield, A. Kenny, A. Mohd Nor, and et al. Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase (DPD) deficiency in patients with colorectal cancer J Clin Oncol 31 suppl; abstr 3627 2013 Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2013
54. Loganayagam A, Marinaki A, Arenas-Hernandez M, Fairbanks L, Sanderson J, Ross PJ. Prediction of severe 5-fluorouracil toxicity in gastro-intestinal cancer chemotherapy: role of DPD deficiency. Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2010.
55. C. Mercier, C. Brunet, C. Yang, C. Dupuis, D. Bagarry-Liegey, S. Duflo, and et al. Pharmacoeconomic study in head and neck cancer patients: impact of prospective DPD deficiency screening with 5-fluorouracil (5-FU) dose tailoring on toxicities-related costs J Clin Oncol 27 suppl; abstr 6515 2009 Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2009
56. M.C. Etienne-Grimaldi, J.-M. Ferrero, F. Thomas, C. Bobin-Dubigeon, J.L. Merlin, F. Pinguet, and et al. A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitabine (cap) J Clin Oncol 31 suppl; abstr e13519 2013 Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago: 20 May 2013
57. M. Del Re, F. Loupakis, A. Michelucci, A. Di Paolo, A. Falcone, P. Simi, and et al. Prediction of fluoropyrimidine toxicities by screening DPYD genetic variants J Clin Oncol 29 suppl; abstr 10524 2011 Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2011
58. D. Papadatos-pastos, K. De Souza, E.M. Karapanagiotou, I. Sandri, A. Marinaki, and J. Mansi DPYD genotyping as a predictive biomarker of toxicity in breast cancer Ann Oncol 25 suppl 4 2014 iv116 iv136 Conference: 39th Congress of the European Society for Medical Oncology (ESMO). http://dx.doi.org/10.1093/annonc/mdu329.
59. D.I. Cubero, F.M. Cruz, P. Santi, I.D. Silva, and G.A. Del Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle Ther Adv Med Oncol 4 4 2012 Jul 167 172
60. R.H.N. Van Schaik Clinical application of pharmacogenetics: where are we now? eJIFCC 4 3-4 2013 1 8
61. W. Siffert Pharmacogenetics in daily routine clinical practice Drug Metabol Drug Interact 27 3 2012 A11 A12 Conference: 6th Santorini Conference Biologie Prospective 2012 Santorini Island Greece
62. Onco Drug Personalized Medicine (ODPM) 2011 www.odpm.fr
63. M. Boisdron-Celle, O. Capitain, J.-P. Metges, V. Guerin-Meyer, R. Faroux, C. Stampfli, and et al. Severe fluoropyrimidines toxicities: a simple and effective way to avoid them. Screen effectively for DPD deficiencies Ann Oncol 23 suppl 4 2012 iv5 iv18 Conference: 37th Congress of the European Society for Medical Oncology (ESMO). http://dx.doi.org/10.1093/annonc/mds151
64. M.J. Deenen, D. Meulendijks, A. Cats, M.K. Sechterberger, J.L. Severens, H. Boot, and et al. Upfront genotyping of DPYD∗2A to individualize fluoropyrimidine therapy: a safety and cost analysis J Clin Oncol 33 2015 Nov (Epub ahead of print)
65. U.S. Food and Drug Administration Label information Xeloda (capecitabine) 2015 www.fda.gov
66. European Medicines Agency Xeloda (capecitabine): EPAR, product information 2015 www.ema.europa.eu
67. H.J. Schmoll, E. van Cutsem, A. Stein, V. Valentini, B. Glimelius, K. Haustermans, and et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making Ann Oncol 23 10 2012 Oct 2479 2516
68. K.E. Caudle, C.F. Thorn, T.E. Klein, J.J. Swen, H.L. McLeod, R.B. Diasio, and et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing Clin Pharmacol Ther 94 6 2013 Dec 640 645
69. Pharmacogenetics working group of the Royal Dutch Society for the Advancement of Pharmacy (KNMP) Background information on DPD pharmacogenetics 2014 www.knmp.nl
70. C.W. van Gils, S. de Groot, S.S. Tan, W.K. Redekop, M. Koopman, C.J.A. Punt, and et al. Real-world resource use and costs of adjuvant treatment for stage III colon cancer Eur J Cancer Care (Engl) 24 3 2015 May 321 332
71. R. von Borstel, J.D. O'Neil, J.A. Saydoff, and M.K. Bamat Uridine triacetate for lethal 5-FU toxicity due to dihydropyrimidine dehydrogenase (DPD) deficiency J Clin Oncol 28 suppl; abstr e13505 2010 Conference: Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago: 20 May 2010